This week, we review the major flagship anti-VEGF agents, pegaptinib, ranibizumab, bevacizumab, aflibercept, as well as some of the flagship clinical trials, including VISION, MARINA, ANCHOR, CATT, and VIEW 1 and 2.
Also, we are doing a survey to assess the impact of the podcast. If you'd like to support us, take this 4 minute survey: bit.ly/2VpPRND